Sinonasal mucoepidermoid carcinoma : a review of the National Cancer Database
Background Primary sinonasal mucoepidermoid carcinoma (SN‐MEC) is a malignancy arising from seromucinous glands of the nasal cavity and paranasal sinuses. Given its rarity, few large‐scale studies have been performed. In this study we describe the incidence and determinants of survival of patients with SN‐MEC leveraging the National Cancer Database (NCDB). Methods This was a retrospective, population‐based cohort study of patients diagnosed with SN‐MEC between 2004 and 2012 within the NCDB. The main outcome measure was overall survival (OS). Results A total of 164 patients were identified. The cohort was composed of 47.6% males. Mean age at diagnosis was 59.7 years. The maxillary sinus was the most common primary site, accounting for 45.7% of cases. Eleven percent of patients presented with nodal disease, whereas 2.1% had distant metastases. Stage IV disease was seen in 30.4% of cases. A total of 79.8% of the patients underwent surgery, 61.0% received radiation therapy, and 15.1% had chemotherapy. OS at 1, 2, and 5 years was 83%, 77.0%, and 57%, respectively. On multivariate analysis, Medicaid insurance status (hazard ratio [HR], 7.29; 95% confidence interval [CI], 1.74‐30.57), advanced tumor size (HR, 4.94; 95% CI, 1.19‐20.5), and advanced nodal disease (N1: HR, 9.48; 95% CI, 1.66‐54.23; N2B: HR, 19.3; 95% CI, 1.07‐350.64) were associated with worse OS. Conclusion Mucoepidermoid carcinoma is the most common salivary gland malignancy but a rare sinonasal malignancy, with 5‐year survival for SN‐MEC approximating 50%. A significant proportion of patients present with advanced disease. Both socioeconomic factors and tumor characteristics are associated with survival..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
International Forum of Allergy & Rhinology - 9(2019), 9, Seite 1046-1053 |
| Beteiligte Personen: |
Triantafillou, Vasiliki [VerfasserIn] |
|---|
| Anmerkungen: |
© 2019 ARS‐AAOA, LLC |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1002/alr.22379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY00125264X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY00125264X | ||
| 003 | DE-627 | ||
| 005 | 20230307102039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2019 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/alr.22379 |2 doi | |
| 028 | 5 | 2 | |a ALR_ALR22379.xml |
| 035 | |a (DE-627)WLY00125264X | ||
| 035 | |a (WILEY)ALR22379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Triantafillou, Vasiliki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sinonasal mucoepidermoid carcinoma |b a review of the National Cancer Database |
| 264 | 1 | |c 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2019 ARS‐AAOA, LLC | ||
| 520 | |a Background Primary sinonasal mucoepidermoid carcinoma (SN‐MEC) is a malignancy arising from seromucinous glands of the nasal cavity and paranasal sinuses. Given its rarity, few large‐scale studies have been performed. In this study we describe the incidence and determinants of survival of patients with SN‐MEC leveraging the National Cancer Database (NCDB). Methods This was a retrospective, population‐based cohort study of patients diagnosed with SN‐MEC between 2004 and 2012 within the NCDB. The main outcome measure was overall survival (OS). Results A total of 164 patients were identified. The cohort was composed of 47.6% males. Mean age at diagnosis was 59.7 years. The maxillary sinus was the most common primary site, accounting for 45.7% of cases. Eleven percent of patients presented with nodal disease, whereas 2.1% had distant metastases. Stage IV disease was seen in 30.4% of cases. A total of 79.8% of the patients underwent surgery, 61.0% received radiation therapy, and 15.1% had chemotherapy. OS at 1, 2, and 5 years was 83%, 77.0%, and 57%, respectively. On multivariate analysis, Medicaid insurance status (hazard ratio [HR], 7.29; 95% confidence interval [CI], 1.74‐30.57), advanced tumor size (HR, 4.94; 95% CI, 1.19‐20.5), and advanced nodal disease (N1: HR, 9.48; 95% CI, 1.66‐54.23; N2B: HR, 19.3; 95% CI, 1.07‐350.64) were associated with worse OS. Conclusion Mucoepidermoid carcinoma is the most common salivary gland malignancy but a rare sinonasal malignancy, with 5‐year survival for SN‐MEC approximating 50%. A significant proportion of patients present with advanced disease. Both socioeconomic factors and tumor characteristics are associated with survival. | ||
| 700 | 1 | |a Maina, Ivy W. |4 aut | |
| 700 | 1 | |a Kuan, Edward C. |4 aut | |
| 700 | 1 | |a Kohanski, Michael A. |4 aut | |
| 700 | 1 | |a Tong, Charles C. |4 aut | |
| 700 | 1 | |a Patel, Neil N. |4 aut | |
| 700 | 1 | |a Carey, Ryan M. |4 aut | |
| 700 | 1 | |a Workman, Alan D. |4 aut | |
| 700 | 1 | |a Palmer, James N. |4 aut | |
| 700 | 1 | |a Adappa, Nithin D. |4 aut | |
| 700 | 1 | |a Brant, Jason A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International Forum of Allergy & Rhinology |g 9(2019), 9, Seite 1046-1053 |w (DE-627)WLY001250981 |x 20426984 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2019 |g number:9 |g pages:1046-1053 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2019 |e 9 |h 1046-1053 |g 8 | ||